Price Chart

Executive Summary

Solid Biosciences Inc. has two S-3 shelf registration statements that became effective on March 31, 2026, enabling the resale of up to 42.8 million shares by selling stockholders from a prior private placement, including pre-funded warrants, and 1.3 million shares held by FA212 LLC. The company will not receive proceeds from these sales, but the potential for significant near-term share issuance creates a dilution overhang.

Key Facts

• Two S-3 shelf registrations became effective on March 31, 2026 (File Nos. 333-294460 and 333-294456).
• First registration covers resale of up to 42,780,739 shares, including 27.8 million shares issuable upon exercise of pre-funded warrants from a March 2026 private placement.
• Second registration covers resale of 1,316,899 shares held by FA212 LLC, acquired in a January 2026 private placement.
• Solid Biosciences will not receive any proceeds from the sale of these shares by the selling stockholders.
• Market cap is $708M; the total registered shares represent approximately 62% of outstanding shares based on current market price of $7.12.

Financial Impact

Up to 44.1 million shares could be sold into the market, representing potential dilution of ~62% of current market capitalization if all shares are sold near current prices (~$314M in total value).

Risk Factors

• Significant near-term downside risk due to potential large-scale selling by private placement investors.
• Dilution overhang may suppress stock price appreciation until resale activity subsides.
• No proceeds to company limits ability to fund operations, increasing future capital raise risk.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status